Argobio and the Institut Pasteur have launched Enodia Therapeutics, a French biotech company dedicated to block and degrade disease-causing proteins for treating cancer, inflammatory diseases and viral infections. Enodia’s first-in-class treatments target the translocon, a key gateway for protein secretion in the cell. “With the convergence of an unprecedented diverse set of small molecules inhibitors […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!